Nodular melanoma (NM) is a particularly dangerous subtype of melanoma due to its swift vertical growth and early metastatic spread. Protheragen offers end-to-end solutions for nodular melanoma (NM) drug and diagnostic development, leveraging cutting-edge technologies and a multidisciplinary expert team.
Overview of Nodular Melanoma (NM)
Nodular Melanoma (NM) is a particularly aggressive subtype of cutaneous melanoma, making up 14%-30% of melanoma cases. Unlike other forms of melanoma, NM is distinct due to its rapid vertical growth phase (VGP), which equates to swift progression. The ability of NM to evolve is characteristic of aggressiveness, making early detection a challenge. Unlike the more common Superficial Spreading Melanoma (SSM), NM doesn't showcase the hallmark features of asymmetry, border irregularity, multicolored, over 6mm diameter, and further growth, which aids in its detection. It's already aggressive and devastatingly prone to being misdiagnosed, which adds to the nightmare of being diagnosed at an advanced stage. Histopathologically, NM is a raised, firm, and smooth nodule with a shiny surface, and at times, ulcerated.
Fig.1 Case analysis of the pathology of nodular melanoma (NM). (Koch E. A.,
et al., 2023)
Diagnostics Development for Nodular Melanoma (NM)
Fluorescence In Situ Hybridization (FISH) for Chromosomal Alterations
Fluorescence in situ hybridization, or FISH, is used to identify chromosomal abnormalities, including amplifications or translocations of genes, which are often seen in NM. FISH enables the identification of particular changes in genes within cells, enhancing the precision and reliability of the diagnosis, particularly regarding the assessment of chromosomal instability. This is often noted in NM.
Immunohistochemistry (IHC) for Protein Expression
Immunohistochemistry is now mainstream in identifying the proteins S100, Melan-A, and HMB-45, which are commonly overexpressed in melanoma cells. With the help of IHC assays, pathologists are able to distinguish NM from other skin lesions through the detection and distribution of particular melanoma markers. This technique is very useful in the diagnosis of amelanotic nodular melanoma, which is pigmentless and can easily get overlooked by standard diagnostic approaches.
Laser Capture Microdissection (LCM) for Tumor Heterogeneity Analysis
Laser capture microdissection (LCM) is a cutting-edge technique that enables the extraction of particular tumor sections from a tissue sample, which is crucial in studying intratumor heterogeneity. LCM can dissect mutant tumor cells from differing mutational regions, which enhances the understanding of clonal evolution in NM. LCM is especially applicable to the study of the therapy modification resistance mechanisms since LCM is able to capture the identified mutations of subclonal populations, which remain undetected in the tumor sample bulk.
Molecular Diagnostics through Next-Generation Sequencing (NGS)
Next-generation sequencing (NGS) helps in the molecular diagnosis of NM by detecting changes in critical genes associated with melanoma, including BRAF, NRAS, and KIT. Throughput sequencing of genomic regions via NGS enables the detailed examination of mutations fueling tumorigenesis in NM. As in the case of BRAF V600E mutations, identifying certain mutations also helps in stratifying patients for BRAF targeted therapies, including vemurafenib and dabrafenib.
Therapeutics Development for Nodular Melanoma (NM)
- Targeted Therapies
Inhibitors of the RAF pathway, for example, vemurafenib and dabrafenib, are targeted therapies developed for the BRAF V600E mutation. Therapeutics with these drugs results in clinically meaningful improvements in response rates, progression-free survival, and overall survival when compared to conventional chemotherapy. Despite these benefits, many patients develop resistance to these therapies within 6 to 7 months, highlighting the need for developing combination therapies.
- Immunotherapies
For NM, as with other cancer types, therapies such as immune checkpoint inhibitors (anti-PD-1 and anti-CTLA-4 antibodies) have shown significant promise. These therapies enhance the body's immune response to the neoplasm, translating to improved patient survival and a subset of patients having durable responses. Further efforts are being directed toward defining predictive biomarkers of response to immunotherapy and creating integrative immunotherapy-targeted therapy combinations.
Table 1. Therapeutics of nodular melanoma (NM).
| Therapeutics |
Drug Name |
Mechanism |
Description |
Stage |
| Targeted Therapy |
Vemurafenib (Zelboraf) |
Inhibits BRAF V600E kinase |
Oral inhibitor for BRAF V600E-mutant melanoma significantly improves progression-free survival (PFS) and overall survival (OS) compared to chemotherapy. |
Approved |
| Targeted Therapy |
Dabrafenib (Tafinlar) |
Inhibits BRAF V600E kinase |
Oral inhibitor for BRAF V600E-mutant melanoma, shows significant improvement in PFS and response rate (RR) compared to chemotherapy. |
Approved |
| Targeted Therapy |
Trametinib (Mekinist) |
Inhibits MEK1/MEK2 |
Oral inhibitor targeting the MEK pathway downstream of BRAF improves PFS and OS in BRAF-mutant melanoma. |
Approved |
| Immunotherapy |
Ipilimumab (Yervoy) |
Inhibits CTLA-4 |
A monoclonal antibody that enhances immune response by blocking CTLA-4 improves survival in metastatic melanoma. |
Approved |
| Immunotherapy |
Pembrolizumab (Keytruda) |
Inhibits PD-1 |
A monoclonal antibody that enhances immune response by blocking PD-1, used in advanced melanoma. |
Approved |
| Immunotherapy |
Nivolumab (Opdivo) |
Inhibits PD-1 |
A monoclonal antibody that enhances immune response by blocking PD-1, often used in combination with ipilimumab. |
Approved |
| Combination Therapy |
Vemurafenib + Cobimetinib |
Dual inhibition of BRAF and MEK |
Combination therapy targeting both BRAF and MEK pathways to overcome resistance and improve outcomes. |
Approved |
| Combination Therapy |
Ipilimumab + Nivolumab |
Dual immune checkpoint inhibition |
Combination of CTLA-4 and PD-1 inhibitors for enhanced immune response in advanced melanoma. |
Approved |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Protheragen provides a complete range of diagnostics and therapeutics development services for nodular melanoma, utilizing advanced technologies and specialized scientific knowledge. Our offerings cover the entire nodular melanoma research process, from early detection and diagnosis to the creation of targeted therapeutic solutions.
Disease Models
- 7,12-dimethylbenz(a)anthracene (DMBA) Induced Models
- 12-O-tetradecanoylphobol-13-acetate (TPA) Induced Models
- NRasQ61R-IRES-Cre Models
- BRafCA/wt Ptenf/f Models
- LSL-KRasG12D Models
- HRasV12G Models
Protheragen's strength in NM diagnostics and therapeutics development stems from our holistic approach and dedication to scientific excellence. Our services focus on in-depth molecular profiling and robust preclinical validation, ensuring that both new therapeutic and diagnostic tools undergo comprehensive evaluation prior to human trials. If you are interested in our services, please feel free to contact us.
References
- Dumitru, Adrian Vasile, et al. "Metastatic Nodular Melanoma with Angiosarcomatous Transdifferentiation—A Case Report and Review of the Literature." Diagnostics 14.13 (2024): 1323.
- Coroiu, Adina, et al. "Patient-identified early clinical warning signs of nodular melanoma: a qualitative study." BMC cancer 21.1 (2021): 371.
- Chiappetta, Caterina, et al. "BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma." Applied Immunohistochemistry & Molecular Morphology 23.3 (2015): 172-177.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
